Xiaoren Tang1, Feng Cao1, Weiyuan Ma2, Yinian Tang3, Bushra Aljahdali1, Mansour Alasir1, I Erdjan Salih1, Serge Dibart1. 1. Henry M. Goldman School of Dental Medicine, Department of Periodontology, 650 Albany Street, Boston, MA, USA. 2. Department of Neurology, Massachusetts General Hospital, Harvard Medical School, 185 Cambridge Street, Boston, MA, USA. 3. School of Medicine, Boston University, 72 East Concord St, Boston, MA, USA.
Abstract
AIM: It is well known that inducing hyperthermia is a type of cancer treatment but some research groups indicate that this treatment is not effective. This article finds and explains the mechanism of this treatment and its possible problems. BACKGROUND: Hyperthermia is commonly known as a state when the temperature of the body rises to a level that can threaten one's health. Hyperthermia is a type of cancer treatment in which body tissue is exposed to high temperatures (up to 45 °C). Research has shown that high temperatures can damage and kill cancer cells, usually with minimal injury to normal tissues. However, this mechanism is not known. MATERIALS AND METHODS: We recently treated cancer cells with different temperatures ranging from 37 °C to 47 °C and further measured their caspase 3 secretion by ELISA, western blot and cell survival rate by microscope. RESULTS: We found that most cancer cells are able to resist hyperthermia more than normal cells most likely via non-activation of caspase3. We also found that hyperthermia-treated (≥41°) cancer cells extend a long pseudopod-like extension in comparison to the same cancer cells under normal conditions. CONCLUSION: Our data here indicates that cancer cells have resistance to higher temperatures compared to normal cells via non-activation of caspase 3. This is a significant issue that needs to be brought to attention as the medical community has always believed that a high temperature treatment can selectively kill cancer/tumor cells. Additionally, we believe that the pseudopod-like extensions of hyperthermia-treated cancer cells must be related to its resistance to hyperthermia.
AIM: It is well known that inducing hyperthermia is a type of cancer treatment but some research groups indicate that this treatment is not effective. This article finds and explains the mechanism of this treatment and its possible problems. BACKGROUND: Hyperthermia is commonly known as a state when the temperature of the body rises to a level that can threaten one's health. Hyperthermia is a type of cancer treatment in which body tissue is exposed to high temperatures (up to 45 °C). Research has shown that high temperatures can damage and kill cancer cells, usually with minimal injury to normal tissues. However, this mechanism is not known. MATERIALS AND METHODS: We recently treated cancer cells with different temperatures ranging from 37 °C to 47 °C and further measured their caspase 3 secretion by ELISA, western blot and cell survival rate by microscope. RESULTS: We found that most cancer cells are able to resist hyperthermia more than normal cells most likely via non-activation of caspase3. We also found that hyperthermia-treated (≥41°) cancer cells extend a long pseudopod-like extension in comparison to the same cancer cells under normal conditions. CONCLUSION: Our data here indicates that cancer cells have resistance to higher temperatures compared to normal cells via non-activation of caspase 3. This is a significant issue that needs to be brought to attention as the medical community has always believed that a high temperature treatment can selectively kill cancer/tumor cells. Additionally, we believe that the pseudopod-like extensions of hyperthermia-treated cancer cells must be related to its resistance to hyperthermia.
Authors: Rolf D Issels; Lars H Lindner; Jaap Verweij; Peter Wust; Peter Reichardt; Baard-Christian Schem; Sultan Abdel-Rahman; Soeren Daugaard; Christoph Salat; Clemens-Martin Wendtner; Zeljko Vujaskovic; Rüdiger Wessalowski; Karl-Walter Jauch; Hans Roland Dürr; Ferdinand Ploner; Andrea Baur-Melnyk; Ulrich Mansmann; Wolfgang Hiddemann; Jean-Yves Blay; Peter Hohenberger Journal: Lancet Oncol Date: 2010-04-29 Impact factor: 41.316
Authors: Pavel S Yarmolenko; Eui Jung Moon; Chelsea Landon; Ashley Manzoor; Daryl W Hochman; Benjamin L Viglianti; Mark W Dewhirst Journal: Int J Hyperthermia Date: 2011 Impact factor: 3.914